CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00102-07v1
14/7/863    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trotter, C.
Right arrow Articles by Borrow, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trotter, C.
Right arrow Articles by Borrow, R.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, July 2007, p. 863-868, Vol. 14, No. 7
1071-412X/07/$08.00+0     doi:10.1128/CVI.00102-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Seroprevalence of Bactericidal and Anti-Outer Membrane Vesicle Antibodies to Neisseria meningitidis Group B in England{triangledown}

Caroline Trotter,1* Jamie Findlow,2 Paul Balmer,2 Ann Holland,2 Rita Barchha,2 Nick Hamer,2 Nick Andrews,3 Elizabeth Miller,4 and Ray Borrow2

Department of Social Medicine, University of Bristol, Bristol, United Kingdom,1 Vaccine Evaluation Unit, Health Protection Agency North West, Manchester, United Kingdom,2 Statistics Unit, Health Protection Agency, London, United Kingdom,3 Immunisation Department, Health Protection Agency, London, United Kingdom4

Received 1 March 2007/ Returned for modification 5 April 2007/ Accepted 3 May 2007

Outer membrane vesicle (OMV) and recombinant protein-based vaccines targeted against multiple strains of group B meningococci are under development. The serum bactericidal antibody (SBA) assay has been designated the surrogate of protection, but the exact cutoff has not been determined. We measured the SBA titers in 2,415 serum samples and the anti-OMV IgG antibody concentrations in 2,672 serum samples representative of the English population to establish a baseline of natural immunity. SBA and anti-OMV IgG antibody titers are high in infants in the first 3 months of life, declining thereafter, presumably as maternal immunity wanes. About 6% of the subjects in the 1- to 11-year-old age group had SBA titers ≥4. During the teenage years, there was a marked increase in the percentage of subjects with SBA titers ≥4, rising to over 50% in 19-year-olds, with about 20% of older adults achieving this titer. The peak in SBA and anti-OMV IgG titers coincided with the peak in meningococcal carriage. Simple mathematical models confirm that the relationship between observed seroprevalence and carriage by age is consistent with carriage inducing SBA and that following an episode of carriage, SBA levels may remain elevated for many months. With the exception of children aged 3 to 11 months, there was no clear relationship between disease incidence and seroprevalence.

* Corresponding author. Mailing address: Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, United Kingdom. Phone: 44 117 928 7220. Fax: 44 117 928 7292. E-mail: caroline.trotter{at}bristol.ac.uk

{triangledown} Published ahead of print on 9 May 2007.

Clinical and Vaccine Immunology, July 2007, p. 863-868, Vol. 14, No. 7
1071-412X/07/$08.00+0     doi:10.1128/CVI.00102-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.